戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 3 domain expressed at levels comparable with human factor VIII.
2  murine, bovine, and porcine factor V and in human factor VIII.
3  for Glu2181-Val2243 significantly less than human factor VIII.
4 sequence for Thr2253-Tyr2332 equally well as human factor VIII.
5  5 (AAV5) vector encoding a B-domain-deleted human factor VIII (AAV5-hFVIII-SQ) in nine men with seve
6 in vivo, we achieved long-term expression of human factors VIII and IX (hFVIII and hFIX) in mouse mod
7              Here we report the structure of human factor VIII C2 domain at 1.5 A resolution.
8    Thus, the inhibitory antibody response to human factor VIII can be reduced by mutagenesis of a B-c
9 n 1b alpha promoter to drive expression of a human factor VIII cDNA construct, transgenic lines were
10 els, although there was no concurrent plasma human factor VIII detectable.
11                                  Recombinant human factor VIII expression levels, in vitro and in viv
12                   Pathogenic variants in the human Factor VIII (F8) gene cause Hemophilia A (HA).
13 racterize the immune response to recombinant human factor VIII (fVIII) and to study new approaches fo
14                Most inhibitory antibodies to human factor VIII (fVIII) bind to epitopes in the A2, ap
15 nts with or without inhibitory antibodies to human factor VIII (FVIII) or IX (FIX).
16 hemophilia A that encodes a B-domain-deleted human factor VIII (FVIII) protein controlled by a hepato
17                            Administration of human factor VIII (FVIII) to FVIII knockout hemophilia m
18 III deficiency require frequent infusions of human factor VIII (hFVIII) concentrates to treat life-th
19     A robust humoral immune response against human factor VIII (hFVIII) following naked DNA transfer
20                   This paper reports loss of human factor VIII (hFVIII) inhibitory antibody in immuno
21                                              Human factor VIII (hFVIII) plasmid gene therapy in hemop
22                            Transgene-derived human factor VIII (hFVIII) protein activity mirrored nat
23 eno-associated virus (rAAV) vectors encoding human factor VIII (hFVIII) were systematically evaluated
24             Persistent therapeutic levels of human factor VIII (hFVIII) would signify a major advance
25 aining an EF1alpha enhancer/promoter driving human factors VIII (hFVIII) or IX (hFIX) complementary D
26                                  Recombinant human factor VIII incubated in solution at 37 degrees C
27                                              Human factor VIII is a plasma glycoprotein that has a cr
28                                              Human factor VIII is present at low concentration in nor
29 ld greater than recombinant B-domain-deleted human factor VIII levels by transient and stable express
30  purified recombinant B domain-deleted (BDD) human factor VIII molecules containing mutations at R484
31 ck of development of antibodies to capsid or human factor VIII proteins.
32 e and subsequent inactivation of recombinant human factor VIII (rhFVIII) and human factor VIIIa (rhFV
33 rmaceutically important protein, recombinant human factor VIII (rhFVIII).
34 he full-length complementary DNA sequence of human factor VIII), second-generation full-length produc
35                      One line had detectable human factor VIII that colocalizes with von Willebrand f
36 actor VIII-deficient background that express human factor VIII under control of the involucrin promot
37 elper-dependent adenoviral vector expressing human factor VIII was administered i.v. to neonatal hemo
38 For this purpose two-dimensional crystals of human factor VIII were grown onto phosphatidylserine-con